The modifiable 45%: where the risk actually sits
The WHO identifies a cluster of tractable variables: tobacco use, alcohol consumption, physical inactivity, social isolation, air pollution exposure, and cardiometabolic conditions — hypertension, diabetes, high cholesterol. These aren't novel discoveries in isolation, but their consolidation into a single risk-reduction framework from an institutional body of this weight shifts the clinical conversation. Alzheimer's disease accounts for an estimated 60–70% of the more than 57 million current cases worldwide, with roughly 10 million new diagnoses per year. The economic load is staggering — $1.3 trillion annually, half of which is unpaid family caregiving. The numbers make a clear case: late-stage intervention is not just medically insufficient, it's economically unsustainable.
What the updated guidelines emphasize is the life-course model — these aren't interventions reserved for the over-65 cohort. Cardiovascular management, social engagement, and physical activity protocols have cumulative neuroprotective effects that compound over decades. The latency between lifestyle modification and observable cognitive outcomes is long, which is precisely why early, consistent action matters more than reactive treatment.
Interventions in, supplements out
The guidelines recommend cognitive training and stimulation activities for adults with normal cognition or mild cognitive impairment, alongside social engagement. Physical activity protocols, dietary adjustments, tobacco cessation, reduced alcohol intake, and hearing-aid use as a risk-reduction tool are all endorsed. A new addition is the recommendation to reduce exposure to air pollution — a variable that has gained significant traction in recent neuroepidemiological research.
Equally notable is what the WHO explicitly does not recommend: supplementation with vitamins B and E, omega-3 polyunsaturated fatty acids, or multivitamins and minerals in the absence of a diagnosed deficiency. The reasoning is direct — insufficient evidence that benefits outweigh potential harms. This is a significant de-endorsement of a multi-billion-dollar supplement market that frequently positions itself as cognitive insurance. For practitioners advising clients on brain-health stacks, this is a hard data point that demands reconsideration.
The offloading question
A related thread worth tracking: emerging discourse around "cognitive offloading" — the reliance on external AI tools to perform memory, reasoning, and planning tasks that would otherwise engage prefrontal and hippocampal circuits. One recent report flags this pattern as a potential dementia-risk amplifier, though the underlying evidence base remains thin and the causal mechanism unconfirmed. The hypothesis aligns with established neuroplasticity principles — circuits that aren't engaged atrophy — but premature to treat as established risk. Monitor, don't panic.
What this changes in practice
For anyone optimizing cognitive longevity, the protocol hierarchy is now clearer than ever: manage cardiometabolic markers aggressively, maintain consistent physical and social activity, reduce exposure to environmental pollutants, and stop relying on micronutrient supplementation as a proxy for behavioral change. The WHO's refusal to endorse popular nootropic supplements without deficiency-level justification is a clinical line in the sand. Cognitive reserve is built through sustained behavioral load, not capsule convenience. The 45% figure means nearly half the dementia burden is, in principle, addressable — the constraint is execution, not knowledge.